Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 259Cyclophosphamide 244Specimen Handling 197fludarabine 175Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 122Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82fludarabine phosphate 79Gemcitabine 79Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 53Temozolomide 48Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × incomplete Freund's adjuvant × 1 year × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡